



Minutes

Date Wednesday, 11/09/2024

Time 10:00 AM

To Sub-Standing Committee

At Virtual, MS Teams

Subject AWERB Standing Committee

Our Ref Doc.UBS.AWERB.11.09.24

Present:

Scientists in attendance for 1a) N/A, 1b) N/A, 1c) N/A & 1d) N/A

Apologies:

Minutes:

1. Project Licences

a) New:

The committee discussed the following:

- Several typographical and grammatical errors that require amending.
- Expansion of the information regarding the publishing of negative results in the Benefits section of the Non-Technical Summary.
- The inclusion of a worst-case scenario in the Project Harms section of the Non-Technical Summary.
- Expansion of the information regarding the model used to replace the use of animals in the Replacement section of the Non-Technical Summary.
- The removal of specific animals from Protocols 1, 2 and 3 if they are not required.
- The inclusion of a body condition core sheet as an example in step 3 of Protocol 5.
- Specific examples required in step 4 of Protocol 5.
- Further details regarding the maximum age of animals for each species in step 1 of Protocol 6.
- The removal of specific references in step 13 of Protocol 6.
- Further clarification required in the Animal Experience section of Protocol 6.
- The inclusion of the use of pilot studies in the Experimental Design section of Protocol 6.

The committee agreed changes were needed before a draft is submitted to the Home Office.

b) New:

was also in attendance)

The committee discussed the following:

- Further explanation required in the Non-Technical Summary.
- The inclusion of further background information in the Non-Technical Summary.



- Further consideration given to the monitoring required and whether what is currently listed is appropriate in the Refinement section and the relevant protocols.
- Further review of the adverse effects listed in Protocol 5.
- Further review of the pilot studies to ensure they are listed in the correct place in step 2 of Protocol 5 and step 2 of Protocol 4.
- The inclusion of an upper limit for dosing in the Describe the procedures that will be carried out during this step section.
- Further review of step 6 in Protocol 5.

The committee agreed changes were needed before a draft is submitted to the Home Office.

c) Amendment: [REDACTED] attended on her behalf)

The committee discussed the following:

- Further expansion of the Scientific Background section.

The committee agreed changes were needed before a draft is submitted to the Home Office.

d) Amendment: [REDACTED]

The committee discussed the following:

- The inclusion of specific routes in the dosing table as well as the daily maximum volumes administered in step 12 of Protocol 7.
- The inclusion of specific statements in step 12 of Protocol 7.
- The inclusion of specific locations for procedures planned in step 2 of Protocol 10.
- Further details required regarding specific procedures planned and that pilot studies will be conducted first in step 3 of Protocol 10.
- The inclusion of the step number in the Experimental Design section of Protocol 10.

The committee agreed changes were needed before a draft is submitted to the Home Office.

2. Minutes of the last meeting

The minutes were not available.

3. Retrospective Reviews [RR]

a) [REDACTED]

The committee discussed the following:

- Amendment of the answer in Section 1.
- The removal of the final part of the table in Section 2.1.
- The removal of specific references in Section 2.3.
- The completion of Section 2.4.
- The inclusion of references to specific animals and whether this is a refinement in Section 3.7.
- Expansion of the answers given in Section 4.9.

b) [REDACTED]

The committee discussed the following:



- Further explanation regarding specific animals in Section 2.4.
- Further statement regarding why specific sections were not applicable in Section 2.9.
- Further clarification around whether animals returned on this retrospective review contributed to the publication listed in Section 3.5.
- Further review of specific dates listed in Section 4.4.
- Expansion of the explanation as to why the benefits listed in Section 4.5 are classed as replacements and refinements.

4. Any other business

None

5. Date of next meeting: 09/10/2024